Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

AIMS: A randomized, double-blind, placebo-controlled study was conducted to investigate the safety and efficacy of mipomersen, an apolipoprotein B-100 (apoB) synthesis inhibitor, in patients who are statin intolerant and at high risk for cardiovascular disease (CVD). METHODS AND RESULTS: Thirty-thre...

Descripción completa

Detalles Bibliográficos
Autores principales: Visser, Maartje E., Wagener, Gilbert, Baker, Brenda F., Geary, Richard S., Donovan, Joanne M., Beuers, Ulrich H.W., Nederveen, Aart J., Verheij, Joanne, Trip, Mieke D., Basart, Dick C.G., Kastelein, John J.P., Stroes, Erik S.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751967/
https://www.ncbi.nlm.nih.gov/pubmed/22507979
http://dx.doi.org/10.1093/eurheartj/ehs023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751967/
https://www.ncbi.nlm.nih.gov/pubmed/22507979
http://dx.doi.org/10.1093/eurheartj/ehs023

Ejemplares similares